282 related articles for article (PubMed ID: 30880459)
1. The significance of chemokines in diffuse large B-cell lymphoma: a systematic review and future insights.
Huang Q; Liu F; Shen J
Future Oncol; 2019 Apr; 15(12):1385-1395. PubMed ID: 30880459
[TBL] [Abstract][Full Text] [Related]
2. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
Takahashi K; Sivina M; Hoellenriegel J; Oki Y; Hagemeister FB; Fayad L; Romaguera JE; Fowler N; Fanale MA; Kwak LW; Samaniego F; Neelapu S; Xiao L; Huang X; Kantarjian H; Keating MJ; Wierda W; Fu K; Chan WC; Vose JM; O'Brien S; Davis RE; Burger JA
Br J Haematol; 2015 Dec; 171(5):726-35. PubMed ID: 26358140
[TBL] [Abstract][Full Text] [Related]
3. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.
Nasser MW; Elbaz M; Ahirwar DK; Ganju RK
Cancer Lett; 2015 Aug; 365(1):11-22. PubMed ID: 25963887
[TBL] [Abstract][Full Text] [Related]
4. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
[TBL] [Abstract][Full Text] [Related]
5. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
6. Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
Jamil MO; Mehta A
Expert Rev Hematol; 2016 May; 9(5):471-7. PubMed ID: 26808217
[TBL] [Abstract][Full Text] [Related]
7. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of liver metastasis.
Kawada K; Hasegawa S; Murakami T; Itatani Y; Hosogi H; Sonoshita M; Kitamura T; Fujishita T; Iwamoto M; Matsumoto T; Matsusue R; Hida K; Akiyama G; Okoshi K; Yamada M; Kawamura J; Taketo MM; Sakai Y
Int J Clin Oncol; 2011 Oct; 16(5):464-72. PubMed ID: 21847533
[TBL] [Abstract][Full Text] [Related]
9. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of pancreatic cancer dissemination: the role of the chemokine system.
Marchesi F; Grizzi F; Laghi L; Mantovani A; Allavena P
Curr Pharm Des; 2012; 18(17):2432-8. PubMed ID: 22372498
[TBL] [Abstract][Full Text] [Related]
11. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
12. Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers.
Jacquelot N; Duong CPM; Belz GT; Zitvogel L
Front Immunol; 2018; 9():2480. PubMed ID: 30420855
[TBL] [Abstract][Full Text] [Related]
13. Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy.
Morein D; Erlichman N; Ben-Baruch A
Front Immunol; 2020; 11():952. PubMed ID: 32582148
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
Xu ZZ; Shen JK; Zhao SQ; Li JM
Leuk Lymphoma; 2018 Jun; 59(6):1451-1460. PubMed ID: 28952842
[TBL] [Abstract][Full Text] [Related]
15. Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma.
Hong JY; Ryu KJ; Lee JY; Park C; Ko YH; Kim WS; Kim SJ
Hematol Oncol; 2017 Dec; 35(4):480-486. PubMed ID: 27943355
[TBL] [Abstract][Full Text] [Related]
16. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
Ben-Barouch S; Kuruvilla J
Expert Opin Investig Drugs; 2020 Jan; 29(1):15-21. PubMed ID: 31847605
[No Abstract] [Full Text] [Related]
17. The chemokine network, a newly discovered target in high grade gliomas.
Domanska UM; Kruizinga RC; den Dunnen WF; Timmer-Bosscha H; de Vries EG; Walenkamp AM
Crit Rev Oncol Hematol; 2011 Aug; 79(2):154-63. PubMed ID: 20709564
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
[TBL] [Abstract][Full Text] [Related]
19. The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research.
Zhou Q; Huang L; Gu Y; Lu H; Feng Z
Cancer Biomark; 2018; 21(4):925-934. PubMed ID: 29504526
[TBL] [Abstract][Full Text] [Related]
20. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.
Moreno MJ; Gallardo A; Novelli S; Mozos A; Aragó M; Pavón MÁ; Céspedes MV; Pallarès V; Falgàs A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
PLoS One; 2018; 13(6):e0198789. PubMed ID: 29920526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
